Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000668673 | SCV000793311 | likely pathogenic | Ellis-van Creveld syndrome | 2017-08-10 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001047674 | SCV001211651 | pathogenic | Ellis-van Creveld syndrome; Curry-Hall syndrome | 2023-07-16 | criteria provided, single submitter | clinical testing | This premature translational stop signal has been observed in individuals with Ellis-van Creveld syndrome (PMID: 19810119, 29229899). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 553266). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. For these reasons, this variant has been classified as Pathogenic. This variant is present in population databases (rs764397417, gnomAD 0.003%). This sequence change creates a premature translational stop signal (p.Glu560*) in the EVC gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in EVC are known to be pathogenic (PMID: 23220543). |
Baylor Genetics | RCV000668673 | SCV001525491 | likely pathogenic | Ellis-van Creveld syndrome | 2020-06-11 | criteria provided, single submitter | clinical testing | This variant was determined to be likely pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. |
Fulgent Genetics, |
RCV001047674 | SCV002813910 | pathogenic | Ellis-van Creveld syndrome; Curry-Hall syndrome | 2022-02-10 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000668673 | SCV002083036 | pathogenic | Ellis-van Creveld syndrome | 2021-04-28 | no assertion criteria provided | clinical testing |